Alrestatin (sodium)

Alrestatin (AY-22284) sodium is an aldose reductase inhibitor. Alrestatin sodium reduces fructose levels in the uterine fluid of mice. Alrestatin sodium interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin sodium decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin sodium enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin sodium can be used in studies related to diabetes and reproductive diseases^[1][2]. In Vitro:Alrestatin (1-5 mg/mL; 15 min) sodium dose-dependently inhibits basal and tyramine-stimulated ³H-norepinephrine release from rat splenic and pancreatic tissue samples in vitro^[1]. In Vivo:Alrestatin (0.75 mmol/kg; intravenous injection; single bolus) sodium significantly enhances glucose-stimulated insulin secretion and improves glucose clearance in fasted, anesthetized non-diabetic male Sprague-Dawley rats, but exerts no effect on basal plasma glucose or insulin levels^[1].
Alrestatin (0.15 μg/μL; intrauterine infusion) sodium significantly reduces fructose levels in mouse uterine fluid without altering glucose or sorbitol levels^[2].
Alrestatin (1.5 mmol/L; intrauterine injection) sodium significantly reduces sperm capacitation rate and fertilization rate in mice, while co-administration of fructose or sorbitol reverses these effects^[2].